195
Participants
Start Date
October 14, 2013
Primary Completion Date
April 13, 2016
Study Completion Date
September 19, 2016
VTX-2337
TLR8 Agonist
Carboplatin
Cisplatin
5-fluorouracil
Placebo
The Bellevue Hospital, New York
Mount Sinai Medical Center, New York
Monter Cancer Center, Lake Success
Stony Brook University Medical Center, Stony Brook
University of Pittsburgh Cancer Institute, Pittsburgh
Pennsylvania State Hershey Cancer Institute, Hershey
Saint Lukes Cancer Centre, Easton
Helen F. Graham Cancer Center, Newark
Walter Reed National Military Medical Center, Bethesda
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
Virginia Cancer Specialists, PD, Fairfax
Wake Forest University Baptist Medical Center, Winston-Salem
University of North Carolina at Chapel Hill, Chapel Hill
Hollings Cancer Center, Charleston
Winship Cancer Institute, Atlanta
Northeast Georgia Cancer Care, LLC, Athens
MD Anderson Cancer Center, Orlando
The West Clinic, Memphis
University Hospitals of Cleveland, Cleveland
Cleveland Clinic, Cleveland
Providence Cancer Institute, Southfield
Karmanos Cancer Institute, Detroit
Henry Ford Health System, Detroit
Medical College of Wisconsin, Milwaukee
Aurora Advanced Healthcare, Inc., Wauwatosa
Northwestern University Feinberg School of Medicine, Chicago
Carle Cancer Center, Urbana
Saint Louis Cancer Care, LLP, Bridgeton
Barnes Jewish Hospital, St Louis
University of Kansas Cancer Center, Westwood
Crescent City Research Consortium, LLC, Marrero
University of Arkansas for Medical Sciences, Little Rock
San Antonio Military Medical Center, Fort Sam Houston
University of Colorado Cancer Center, Aurora
VA Eastern Colorado Healthcare System, Denver
Nevada Cancer Research Foundation, Las Vegas
University of California Norris Comprehensive Cancer Center, Los Angeles
Tower Hematology Oncology Medical Group, Beverly Hills
California Cancer Associates for Research and Excellence (CCARE), Escondido
University of California San Diego Moores Cancer Center, La Jolla
Tripler Army Medical Center, Honolulu
Providence Cancer Center, Portland
Saint Charles Medical Center, Bend
Madigan Army Medical Center, Tacoma
Medical Oncology Associates, PS, Spokane
Robert W. Veith, MD, LLC, Metairie
Maine Center for Cancer Medicine, Scarborough
Dana Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
Oncology and Hematology Specialists, P.A., Denville
Hackensack University Medical Center, Hackensack
University of Cincinnati, Cincinnati
University of Texas Southwestern Medical Center at Dallas, Dallas
Lead Sponsor
Celgene
INDUSTRY